Cognitive Decline, Delirium, Frailty
Conditions
Keywords
delirium, cognitive decline, frailty, heart surgery
Brief summary
A parallel-group treatment, five-centre, participant and investigator masked, three-arm study to assess the safety and effectiveness of dexmedetomidine or clonidine infusion compared to placebo for the prevention of delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery.
Detailed description
Delirium is a major public health concern without therapeutic options. It is an acute disturbance of attention and cognition, precipitated by an acute somatic condition. Delirious patients are often subject to off-label treatment with psychotropic drugs that have dubious effects. The intravenous alpha-2-adrenergic receptor agonist dexmedetomidine, attenuating sympathetic nervous system activity, shows promise as treatment for delirium, but its use is limited to intensive care units (ICU). Its long-term cognitive effects are unknown. Clonidine is a pharmacodynamically similar drug that can be given orally and has been used for decades as an antihypertensive agent, but is else sparsely studied. ALPHA2PREVENT will be a three-armed randomised controlled trial to study 1) whether repurposing of clonidine can represent a novel treatment option for delirium, and 2) the possible effects of both dexmedetomidine and clonidine on long-term cognitive trajectories, motor activity patterns, patient rated outcome measures and biomarkers of neuronal injury.
Interventions
DRUGDexmedetomidine
Continous intravenous infusion
DRUGClonidine
Continous intravenous infusion
DRUGNatriumchlorid
Continous intravenous infusion NaCl
Sponsors
Haukeland University Hospital
University Hospital of North Norway
UMC Utrecht
Sahlgrenska University Hospital
St. Olavs Hospital
Oslo University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
A parallel-group treatment, five-centre, participant and investigator masked, three-arm study to assess the safety and effectiveness of dexmedetomidine or clonidine infusion compared to placebo for the prevention of delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery.
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply: 1. Participant must be ≥70 years old at the time of signing the informed consent. 2. Participant must be accepted for cardiac surgery with cardiopulmonary bypass. The surgical procedures may constitute 1) coronary bypass grafting, 2) tricuspid, mitral, or aortic valve replacement or repair, 3) surgery on the ascending aorta, and 4) the combination any of these procedures. 3. Participant must be capable of giving signed informed consent.
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply: 4. Preoperative delirium 5. Known hypersensitivity to the active ingredient or components of the product 6. Bradycardia due to sick-sinus-syndrome, 2nd or 3rd degree AV-block (if not treated with pacemaker) or any other reason causing HR \<50 bpm at time of inclusion 7. Uncontrolled hypotension 8. Ischemic stroke or transitory ischemic attack the last month or critical peripheral ischemia 9. Acute coronary syndrome last 24 hours. Acute coronary syndrome is defined according to international guidelines 10. Left ventricular ejection fraction \< 40% 11. Severe renal impairment (estimated GFR \<20ml/min) or expected requirement for renal replacement therapy 12. Severe hepatic dysfunction (liver enzyme three times the upper limit of normal together with a serum albumin concentration below the normal reference limit) 13. Reduced peripheral autonomous activity (e.g. spinal cord injury) 14. Current use of tricyclic antidepressants, monoamine reuptake inhibitors or ciclosporin 15. Endocarditis or sepsis 16. Pheochromocytoma 17. Planned deep hypothermia and circulatory arrest 18. Emergency surgery, defined as less than 24 hours from admission to surgery 19. Previously included in this study 20. Not speaking or reading Norwegian 21. Any other condition as evaluated by the treating physician
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative delirium | Up to 7 days | Cumulative incidence of postoperative delirium, as diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of coma | Up to 7 days | Incidence of coma, as measured by Richmond Agitation Sedation Scale (-5 to +5) |
| Incidence of death, coma or postoperative delirium | Up to 7 days | Incidence of death, coma or postoperative delirium, as described above |
| Number of delirium days postoperatively | Up to 7 days | Number of delirium days postoperatively, as diagnosed according to DSM-5 criteria |
| Delirium severity | Up to 7 days | Delirium severity, as measured by Confusion Assessment Method for Intensive Care Units-7 (CAM-ICU)-7 |
| Motor activity patterns | 6 months | Motor activity patterns, assessed with body worn accelerometers |
| Change in cognitive function between inclusion and after 1 and 6 months | 6 months | Change in cognitive function between inclusion and after 1 and 6 months, as graded by Montreal Cognitive Assessment (MoCA), 10-words memory task from The Consortium Establish a Registry for Alzheimer's Disease (CERAD), digit span tests, Trail making tests (TMT) A and B, semantic and phonemic verbal fluency, and measured repeatedly preoperatively and 1 and 6 months after surgery |
| Serum concentrations of NFL and p-tau181 | 5 days postoperatively | Comparison to inclusion of serum concentrations of neurofilament light (NFL) and p-tau181 1, 3 and 5 days postoperatively |
| Estimate associations between frailty and the other endpoints | 6 months | Estimate associations between frailty and the other endpoints, as described above |
| Safety and tolerability | 6 months | Safety and tolerability as determined by the numbers of Adverse Events (AEs), serious AEs (SAEs) and suspected unexpected serious adverse reactions (SUSARs), and vital signs; blood pressure (BP), heart rate (HR), peripheral oxygen saturation (SpO2) postoperatively |
| Interaction between preoperative frailty and treatment on delirium and the other endpoints | 6 months | Interaction between preoperative frailty and treatment on delirium and the other endpoints, as described above |
| Change in frailty status between inclusion and after 1 and 6 months | 6 months | Change in frailty status between inclusion and after 1 and 6 months, as graded by the frailty index (FI) and essential frailty toolset (EFT) (section 8.1.3), and measured repeatedly preoperatively and 1 and 6 months after surgery |
| Comparison of change in frailty status between inclusion and after 1 and 6 months | 6 months | Comparison of change in frailty status between inclusion and after 1 and 6 months (as described above) between patients with or without postoperative delirium. |
| Change in patient rated health status between inclusion and after 1 and 6 months | 6 months | Change in patient rated health status between inclusion and after 1 and 6 months, as assessed by the EQ-5D-5L questionnaire preoperatively and 1 and 6 months postoperatively |
Other
| Measure | Time frame | Description |
|---|---|---|
| Additional biomarkers | 5 days postoperatively | Additional biomarkers of neural injury, inflammation or neurotransmission may be explored |
Countries
Norway
Contacts
Primary ContactBjørn Erik Neerland, PhD
Backup ContactTorgeir Bruun Wyller, Professor
Outcome results
None listed